Cargando…
Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease
Infection with novel SARS-CoV-2 carries significant morbidity and mortality in patients with pulmonary compromise, such as lung cancer, autoimmune disease, and pneumonia. For early stages of mild to moderate disease, care is entirely supportive. Antiviral drugs such as remdesivir may be of some bene...
Autores principales: | Yates, Paul A., Newman, Steven A., Oshry, Lauren J., Glassman, Robert H., Leone, Ashton M., Reichel, Elias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476338/ https://www.ncbi.nlm.nih.gov/pubmed/32873175 http://dx.doi.org/10.1177/1753466620951053 |
Ejemplares similares
-
ATYPICAL MACULOPATHY IN A PATIENT WITH LIGHT CHAIN DEPOSITION DISEASE MIMICKING ADVANCED GEOGRAPHIC ATROPHY
por: Crawford, Courtney, et al.
Publicado: (2017) -
Comorbidities in patients with COPD and pulmonary rehabilitation: do they matter?
por: Franssen, Frits M.E., et al.
Publicado: (2014) -
Doxycycline in the Coronavirus Disease 2019 Therapy
por: Dorobisz, Karolina, et al.
Publicado: (2021) -
Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update
por: Vonk Noordegraaf, Anton, et al.
Publicado: (2019) -
Risk stratification and medical therapy of pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2019)